GLYC: רווח נקי למניה ב-12 החודשים האחרונים GlycoMimetics, Inc.
GlycoMimetics, Inc. (GLYC) develops targeted carbohydrate mimetics to combat leukemia, relying heavily on patents and FDA verdicts. The EPS trend over the last 12 months illustrates this volatility, where the value -0.46 represents the current figure. A lack of revenue and trial uncertainty leave the company vulnerable, while its environmental strategy is limited solely to the proper disposal of laboratory waste.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_GLYC_-_GlycoMimetics-Inc._-_Earnings-per-share-for-the-last-four-quarters "GlycoMimetics Inc. - רווח נקי למניה (EPS TTM) GLYC (תקופה 04.07.2022 - 16.06.2025) | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת GlycoMimetics, Inc.
Asset quality is assessed through the actual yield of each share. This metric calculates the total annual net income divided by the total number of securities. By analyzing the TTM fundamental earnings per share trend, an investor identifies hidden financial risks. For GlycoMimetics, Inc. (GLYC), this indicator reflects the cost efficiency of developing oncology drugs. Scientific synergy with medical centers should convert into growth for this metric.
